Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus.
Talip E ErogluRuben CoronelCoert J ZuurbierMarieke BlomAnthonius de BoerPatrick C SouvereinPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
SGLT-2i use was associated with reduced all-cause mortality in patients with type 2 diabetes. The association between use of SGLT-2i and reduced risk of SCA was not statistically significant.